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The penetration of antimicrobials in pig tonsils is hardly known. The objec-
tive of the study was to quantify the tildipirosin (TD) penetration in tonsils.
Animals were randomly divided into six groups (control, T1, T2 (1), T2(5),
T2(10), and T2(15)) of eight animals. T1 and T2 groups received a dose of 2
and 4 mg of TD/kg bw in one shot (Zuprevo MSD Animal Health), respec-
tively, and the control group received 2 mL of saline solution. The animals
were sacrificed by intravenous administration of pentobarbital sodium 24 h
after finishing the treatment for the control, T1, and T2(1) groups, whereas
animals of T2(5), T2(10), and T2(15) groups were sacrificed at 5, 10, and
15 days, post-treatment, respectively. Tonsils and blood samples were taken
at necropsy to obtain plasma, and the tildipirosin concentration was deter-
mined by high-performance liquid chromatography with tandem mass spec-
trometry detection. The concentration in plasma was always significantly
lower than in tonsil. Average TD tonsil concentrations increased significantly
in a dose-dependent manner, and the tonsil TD vs. plasma TD concentration
ratio was approximately 75 for the doses of 2 and 4 mg of TD/kg bw at 24 h
post-treatment. Moreover, the maximum concentration of tildipirosin in tonsil
was observed at 1 day postadministration, and this concentration decreased
gradually from this day until 15 days postadministration for the dose of
4 mg of TD/kg bw. Finally, the ratio AUCtonsil/AUCplasma was 97.9, and the
T1/2 (h) was clearly higher in tonsil than in plasma.
(Paper received 15 December 2014; accepted for publication 13 July 2015)
Lorenzo Fraile, Departament de Produccio Animal, ETSEA, University de Lleida,
Lleida, Spain. E-mail: lorenzo.fraile@prodan.udl.cat5
Tildipirosin (TD) is a semisynthetic tylosin analog, which has a
unique chemical structure characterized by two piperidine sub-
stituents on C20 and C23, and a basic mycaminose sugar moi-
ety at C5 of the macrocyclic lactone ring that has been
approved for the treatment for respiratory diseases in pigs and
cattle (EMA, 2011). This macrolide is rapidly absorbed and
extensively distributed to the site of respiratory infection. In
lung, mean TD concentrations were characterized by a peak
on day 1 and a slow decline until 17 days after administration
(Rose et al., 2013). The long persistence of TD in the body is
demonstrated further by a pronounced terminal elimination
half-life of about 7 days in lung. As a class, the macrolides are
characterized by extensive partitioning into tissues, where they
achieve multifold higher concentrations relative to those
observed in the blood plasma (Nightingale, 1997)6 . The magni-
tude of the local accumulation and long persistence of TD in
the lung results in a convenient treatment regimen (single
administration) and positive clinical outcome rates for respira-
tory conditions (Rose et al., 2013).
One critical point in the epidemiology of Actinobacillus
pleuropneumoniae (APP) is that pigs can become asymptomatic
carriers of this micro-organism in their tonsils for long periods.
In the literature, antimicrobial treatments have been used to
eradicate APP from tonsils. Thus, Fittipaldi et al. (2005) used
feed medicated with tilmicosin phosphate for 30 days but
found that the tonsils of the majority of animals were APP
PCR positive 30 days later. Other authors were also unable to
eliminate this bacterium from tonsils (Angen et al., 2008) with
the usual administration schedule recommended for tulathro-
mycin (2.5 mg/kg bw/one shot). Finally, an eradication pro-
gram that includes sow medication with enrofloxacin (a
fluoroquinolone) seemed to be successful, but specific studies to
demonstrate the presence or not of APP in tonsils were not
performed (Bækbo, 2006). Thus, the goal of this study was to
quantify the TD penetration in tonsils and to characterize its
pharmacokinetic profile at the registered dose (4 mg of TD/kg
bw) as a first step to check the potential use of this molecule to
eradicate APP from tonsils in carrier animals.
Forty-eight 2-month-old clinically healthy hybrid pigs (Lan-
drace 9 Large white) were selected for this study. Animals
were randomly divided into six groups (control, T1, T2 (1), T2
(5), T2(10), and T2(15)) of eight animals. T1 and T2 groups
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received a dose of 2 and 4 mg of TD/kg bw in one shot, respec-
tively, and the control group received 2 mL of saline solution
(NaCl 0.9%). Depending on the pig weight, the administration
volume of 40 mg of TD/mL (Zuprevo; MSD Animal Health)
ranged from 0.75 to 1 and 1.5 to 2 mL for the 2 and 4 mg
dose of TD/kg bw, respectively. All the treatments were admin-
istered intramuscularly in the neck. Groups were balanced by
gender and weight. The animals were sacrificed by intravenous
administration of pentobarbital sodium 24 h after finishing the
treatment for the control, T1, and T2(1) groups, whereas ani-
mals of T2(5), T2(10), and T2(15) were sacrificed at 5, 10,
and 15 days, post-treatment, respectively. Tonsils and blood
samples were taken at necropsy to quantify the concentration
of TD (Intervet Innovation GmbH, a member of the MSD Ani-
mal Health group in Schwabenheim, Germany). Briefly, these
samples were assayed for TD using high-performance liquid
chromatography (HPLC) with a Spark HySphere C18 HD car-
tridge (Spark Holland B.V.7 ) with tandem mass spectroscopy
detection (LC/MS/MS) after solid-phase extraction (Online-SPE).
Details of the extraction method ad phase mobile have been
previously published (Rose et al., 2013). Quantitation of tildi-
pirosin was performed using a standard curve consisting of
eight concentrations ranging from 0.025 to 10 lg/mL
(plasma) and 0.125 to 50 lg/g (tonsil homogenate) of tildipir-
osin. The lower limit of quantification (LLOQ) was 0.025 lg/
mL (plasma) and 0.125 lg/g for tonsils.
Plasma and tonsil PK parameters were determined based on
group mean values with a noncompartmental analysis using
the computer program Pharsight WinNonlin software version
5.1.1 and 5.2.1 (Pharsight Corporation, St. Louis, MO, USA).
Area under the curve (AUC) of plasma and tonsil concentra-
tion vs. time (AUCplasma and AUCtonsil) was measured via a lin-
ear trapezoidal method with linear interpolation. The start of
the terminal elimination phase was set to 24 h after adminis-
tration as previously published (Rose et al., 2013). kz is defined
as the first-order rate constant associated with the terminal
(log-linear) portion of the curve, which is estimated by linear
regression of time vs. logarithmic concentration. Finally, the
terminal half-life (T1/2) was calculated as log102/kz.
All statistical analyses were carried out using R software (R
Core Team, 2012)8 . For these analyses, the individual pig was
the experimental unit. The significance level (a) was set at
0.05. Shapiro–Wilk0s and Levene tests were used to evaluate
the normality of the distribution of the variables and the
homogeneity of variances, respectively. A nonparametric (Wil-
coxon test) was chosen to compare the different TD concentra-
tion observed in plasma and tonsils between groups.
Average tildipirosin plasma (ATPC) and tonsil (ATTC) con-
centration for the control, T1, and T2(1) group increased sig-
nificantly (P < 0.05) in a dose-dependent manner, and the
tonsil TD vs. plasma TD concentration ratio was approximately
75 at 24 h postadministration for the doses of 2 and 4 mg of
TD/kg bw. On the other hand, the concentration in plasma
was always significantly lower (P < 0.05) than in tonsil for the
groups treated with 4 mg of TD/kg bw at 1, 5, 10, and
15 days post-treatment, while the maximum concentration of
tildipirosin in tonsil was observed at 1 day postadministration
with a gradual decrease until 15 days postadministration
(Fig. 1). Moreover, the ratio AUCtonsil/AUCplasma was 97.9, and
the T1/2 (h) was clearly higher in tonsil than in plasma
(Table 1).
Tildipirosin exerts a positive role in the treatment and control
of bovine and swine respiratory disease (EMA, 2011). This clini-
cal efficacy can be explained by the extraordinary lung selectiv-
ity and concentration vs. time profile of this macrolide in
pulmonary tissue (Rose et al., 2013). In the particular case to
eliminate bacteria with antimicrobials from tonsils, the informa-
tion generated in this study is necessary to know the pharma-
cokinetic profile of TD in tonsils because a similar
pharmacokinetic profile cannot be assumed between airway
compartments and tonsil. The concentration of tildipirosin in
lung and bronchoalveolar lavage far exceeded plasma concen-
trations (Rose et al., 2013) as it has been also described for tula-
thromycin in pigs (Villarino et al., 2013a,b). The basic nature of
the drug and a limited degree of ionization at physiological pH
Table 1. Tildipirosin concentrations and its pharmacokinetic parame-
ters in tonsil and blood plasma (mean+SD) and its ratio thereof after
single i.m administration of 40 mg/mL tildipirosin solution for injection
at 4 mg of TD/kg bw
Time after
administration
(hours)
Tonsil
concentration
(ng/g)
Plasma
concentration
(ng/mL)
Ratio of
tonsil vs.
plasma
24 3620  386.3 48  14 75.4
120 2041.3  740 20 + 11 102
240 1043.9  292 11 + 6 95
360 590.1  136 b.l.q n.a.
Pharmacokinetic parameters (calculated from mean values)
AUClast (hlg/g
or hlg/mL)
837.796 8.556 97.9
kz (/h) 0.00235 0.00335 0.70
T1/2 (h) 295 207 1.43
b.l.q, Below limit of quantification; n.a. Not applicable.
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Fig. 1. Mean + SD tildipirosin concentration in porcine plasma and
tonsil obtained postmortem at necropsy following a single i.m adminis-
tration at a dose of 4 mg of TD/kg bw.
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represent features that favor the distribution of the drug into
extravascular compartments (Cox et al., 2010). The drug pene-
trated rapidly into the airways and tonsil, but concentration
declined slowly. The drug concentration decay occurred faster in
plasma than in the airways and tonsil. This result might indicate
that different factors, other than/or in addition to simple drug
diffusion, play a role in the process of movement of tildipirosin in
and out between the plasma and the airway compartments and
tonsils. The ratio TD tonsil vs. plasma concentration (75) is
lower than the ratio TD lung vs. plasma concentration (83) at
Tmax (24 h postadministration) using a dose of 4 mg of TD/bw
in one shot (Rose et al., 2013). In contrast, the ratio AUCtonsil/
AUClung is 93.5% although the AUCtonsil could be overestimated
due to the lack of tildipirosin determinations before 24 h postad-
ministration. In any case, this result suggests that the exposure
of the lung to this drug (Rose et al., 2013) is higher than the
exposure at tonsil level.
Macrolides have been classified as time-dependent killing
drugs, best described by the PK/PD parameter time above MIC
(T > MIC). However, for newer macrolides such as tulathromy-
cin, gamithromycin, and tilmicosin, the plasma AUC/MIC ratio
appears to be the best correlate with successful outcome (Evans,
2005; Lees et al., 2006). In this case, the tildipirosin MIC90 for
APP strains is 2 lg/mL (Rose et al., 2013). On the basis of tildi-
pirosin concentration in tonsil and MIC90 for APP, the mean
tonsil tildipirosin concentration is above the MIC90 for APP for
about 5 days. However, this information is insufficient to predict
whether the tonsil concentration is enough to eliminate this bac-
terium from this tissue and in vivo studies with carrier pigs are
needed to confirm this assumption. The results from this study
provide a good base to start working in this area.
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